Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 13, 2010

View Archived Issues

DC-based TaReNef AIDS vaccine is safe and immunogenic in phase I/II trial

Pfizer's antibacterial MC-1 shows promising preclinical activity

Snapshots: Recent data on the antibacterial activity of CXA-101

First-in-human data disclosed on NIBR-6465

Pfizer introduces new candidates for inhalation therapy of COPD

Sigma-Tau describes new adenosine A2A receptor antagonists

Prosidion discloses new GPR119 receptor agonists

Phase I/II trials suggest efficacy of Neuvax vaccine in prevention of breast cancer recurrence

Auxilium begins phase III Xiaflex studies in Peyronie's disease

FDA sets date for end-of-phase II meeting on NTx-265

State University of New York, Albany claims novel antiestrogens

Exelixis and Bristol-Myers Squibb collaborate on multiple small-molecule programs

CureVac presents phase I/IIa data on CV-9103 in prostate cancer

GSK describes new tyrosine-protein kinase ITK/TSK inhibitors

Jazz Pharma receives FDA complete response letter regarding JZP-6 for fibromyalgia

FDA approves delayed-release risedronate sodium for postmenopausal osteoporosis

Researchers synthesize new oncolytic gold complexes

Novartis to use ImmunoGen's TAP technology to develop anticancer therapeutics

Seattle Genetics reports phase II data on brentuximab vedotin in lymphoma

ArQule and Daiichi Sankyo agree with FDA on SPA for phase III ARQ-197 trial

Novo Nordisk tenders all of its shares in ZymoGenetics to Bristol-Myers Squibb

FDA approves Vivitrol for prevention of relapse to opioid dependence

Phase III Multikine trial in head and neck cancer approved in Taiwan

Jubilant Organosys becomes Jubilant Life Sciences

Lundbeck acquires exclusive commercial rights to Sycrest outside U.S., China and Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...